Colorectal cancer is characterised by high molecular heterogeneity and genomic alterations in common cancer drivers, including RAS, BRAF, and mismatch repair genes, which are routinely assessed to inform precision treatments. However, constant clonal evolution is common and leads to therapeutic resistance. Longitudinal molecular analysis of integrated tissue and liquid biopsies is essential to monitor the molecular evolution of colorectal cancer during the continuum of care and inform sequential adaptive therapies based on real-time genomic changes.
[Perspectives] ICGC-ARGO precision medicine: targeted therapy according to longitudinal assessment of tumour heterogeneity in colorectal cancer
Leggi l'articolo originale